BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Aug 27, 2012
 |  BC Extra  |  Clinical News

Novartis' LCZ696 meets heart failure endpoint

Novartis AG (NYSE:NVS; SIX:NOVN) said LCZ696 met the primary endpoint in the Phase II PARAMOUNT trial to treat heart failure with preserved ejection fraction (HF-PEF). The product significantly reduced N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker of left ventricular wall...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >